Legend Biotech Corporation (Nasdaq: LEGN) has entered into an exclusive, global license agreement with Swiss pharma giant Novartis (NOVN: VX).
The collaboration surrounds certain Legend CAR-T cell therapies targeting DLL3, including LB2102.
Novartis has been granted the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and may apply its T-Charge platform to their manufacture.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze